Prospects and challenges of yellow flesh pangasius in international markets: secondary and primary evidence from Bangladesh.

The projected increase in aquaculture production by 2030 will mostly occur in countries of Asia and Africa, including Bangladesh. The pangasius (Pangasianodon hypophthalmus) produced in Bangladesh, the second-largest producer globally, is mainly consumed by low-income domestic consumers and is poorly demanded in international markets. One reason for this is the yellow flesh of fish; consumers generally in mainstream international markets prefer to fish with white flesh. Reviewing secondary evidence and analyzing primary data, this article assesses the underlying reasons for the discolored pangasius flesh in Bangladesh and synthesizes strategies for avoiding discoloration to induce exports. The findings indicate that farming practices with high stocking density, infrequent water exchange, high organic matter in pond water, and the growth of carotenoid-containing cyanobacteria contribute to the discoloration of pangasius flesh. Artificial and natural pigments in feed and poor post-harvest handling of fish are also contributing factors. Furthermore, a positive correlation between water exchange, price, and yield at the farm is found, which indicates that farm-gate price and yield per hectare can increase with more frequent water exchange. The findings of this study provide strong evidence that improved aquaculture practices can solve the problem of discolored pangasius flesh and establish an export-oriented pangasius industry in Bangladesh.

Valproate-induced hyperammonemia in juvenile ceroid lipofuscinosis (Batten disease).

PURPOSE: Valproate-induced hyperammonemia (VHA) and hyperammonemic encephalopathy (VHE) are well-known complications of valproate (VPA) treatment. Currently recognised risk factors for VHE include a high VPA dosage, the need for polytherapy and long duration of treatment. Despite the severe nature of the epilepsy, presence of concomitant psychiatric manifestations, and frequent need for poly-pharmacy associated with juvenile ceroid lipofuscinosis (JNCL, Batten disease) neither this disorder nor other subtypes of neuronal ceroid lipofuscinosis have previously been identified as risk factors for VHA/VHE. The aim of the present publication is to describe four cases with VHE in a well-defined Danish population of JNCL. METHOD: An examination of medical records of all 35 patients with JNCL in Denmark was conducted and revealed fourteen patients treated with VPA. RESULTS: Four patients treated with VPA developed VHE. All patients were prescribed VPA in standard dosages, had normal plasma concentrations of VPA and received antiepileptic drug (AED) polytherapy. Symptoms occurred shortly after commencement or increase in dose of VPA, and were quickly reversible upon discontinuation of VPA. Carnitine supplement was administrated in two patients, which resulted in resolution of symptoms and normalized ammonium levels. CONCLUSION: Patients with JNCL are in great risk of developing VHA and VHE due to a high rate of polytherapy. Furthermore, studies have shown that carnitine level can be depressed in JNCL, which may increase the risk of VHA and VHE. We recommend that increased attention should be given to these patients.

Transcriptional down-regulation of the platelet ADP receptor P2Y(12) and clusterin in patients with systemic lupus erythematosus.

Cardiovascular complications are common in systemic lupus erythematosus (SLE) and myocardial infarctions are the leading cause of increased mortality. The ADP receptor P2Y(12) plays a central role in platelet activation and the P2Y(12) blocker clopidogrel reduces the incidence of cardiovascular events. Clusterin, a complement inhibitory protein suggested to be involved in the pathogenesis of SLE, has been found recently in a microarray study to be expressed at very high levels in platelets. Using a new protocol for mRNA quantification in platelets we set out to study if gene expression is altered in SLE patients compared with a healthy control group. Quantitative assay based on real-time PCR was used to measure mRNA expression, Western blot for P2 receptor protein expression and PFA-100 for platelet aggregation. The P2Y(12) receptor expression was decreased in SLE compared to the controls (P < 0.05), while expression of P2Y(1) and P2X(1) were unaltered. These findings were consistent at the protein level. The clusterin mRNA expression was very high. However, SLE patients had significantly lower levels than controls (P < 0.05). Platelet aggregation was similar in both groups. It may be suggested that a decreased level of P2Y(12) receptors could represent a protective response in SLE against thrombotic complications. Lowered clusterin levels could be involved in the pathogenesis of SLE due to decreased protective effects. These findings could help to achieve a better understanding of the platelet function in SLE and serve as a guide for further research and drug use.